Comparative Pharmacology
Head-to-head clinical analysis: ORTHO EVRA versus ORTHO NOVUM 10 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO EVRA versus ORTHO NOVUM 10 21.
ORTHO EVRA vs ORTHO-NOVUM 10-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing ethinyl estradiol and norelgestromin. Ethinyl estradiol suppresses gonadotropin (FSH and LH) release, preventing ovulation. Norelgestromin is a progestin that also inhibits ovulation and induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining, reducing sperm penetration and implantation.
Transdermal: Apply one patch (releases 150 mcg norelgestromin and 20 mcg ethinyl estradiol per 24 hours) weekly for 3 weeks, followed by 1 patch-free week. Apply to clean, dry, intact skin on lower abdomen, buttock, upper arm, or upper torso (excluding breasts).
1 tablet (1 mg norethindrone, 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of no tablets.
None Documented
None Documented
Norelgestromin: ~28 hours (range 21-36) allowing weekly dosing; Ethinyl estradiol: ~17 hours (range 13-21)
Norethindrone 5-14 hours (mean 8 hours), ethinyl estradiol 7-20 hours (mean 13 hours). Steady-state achieved in 5-10 days.
Renal: ~50% (as glucuronide conjugates of norelgestromin and ethinyl estradiol); Fecal: ~35% (as metabolites); Biliary: minor
Renal approximately 50-60% as metabolites, biliary/fecal approximately 30-40% as metabolites and unchanged drug.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive